Financial Performance - Operating revenue for the reporting period was ¥68,520,281.05, representing a 51.59% increase compared to the same period last year[8]. - Net profit attributable to shareholders of the listed company was ¥29,299,623.52, up 55.24% year-on-year[8]. - Basic earnings per share increased by 30.00% to ¥0.26 for the reporting period[8]. - Total operating revenue for the current period reached ¥68,520,281.05, an increase of 51.5% compared to ¥45,202,480.24 in the previous period[39]. - Net profit for the current period was ¥29,299,623.52, representing a significant increase of 55.4% from ¥18,873,301.36 in the previous period[40]. - Total revenue grew by 33.90% to CNY 198,605,748, reflecting strong business performance[17]. - Net profit for the period was CNY 60,522,372.34, representing a 45.9% increase from CNY 41,471,955.10 in the same period last year[48]. - Total profit for the period was CNY 66,422,510.87, compared to CNY 44,606,759.62, reflecting a growth of 48.9%[48]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥781,452,688.64, an increase of 77.72% compared to the end of the previous year[8]. - The company's total assets increased to ¥822,446,445.52, compared to ¥451,698,518.47 at the beginning of the period, marking an increase of 82%[36]. - The total liabilities decreased to RMB 108,526,981.76 from RMB 132,600,828.60, showing a reduction of about 18.1%[33]. - The total liabilities increased to ¥116,355,185.48 from ¥109,191,091.30, reflecting a growth of 6.3%[37]. Cash Flow - The net cash flow from operating activities for the year-to-date reached ¥35,137,864.78, a significant increase of 456.27%[8]. - The cash inflow from operating activities totaled CNY 221,464,868.33, an increase of 19.25% compared to CNY 185,672,603.98 in the previous period[55]. - The net cash flow from operating activities was CNY 35,137,864.78, significantly up from CNY 6,316,690.89 in the same period last year[55]. - The cash inflow from financing activities amounted to CNY 326,782,863.45, a significant increase from CNY 43,105,700.00 in the previous period[58]. - The net cash flow from financing activities was CNY 282,747,197.09, compared to -CNY 9,831,322.17 in the same period last year[56]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,743[12]. - The largest shareholder, Fan Minhua, holds 35.16% of the shares, totaling 42,932,000 shares[12]. Investments and Expenses - The company’s investment payments increased by 853.12% to CNY 286,616,160, indicating a rise in external financial management[17]. - Total operating costs amounted to ¥37,394,616.22, up from ¥26,277,042.90, reflecting a year-over-year increase of 42.5%[39]. - Sales expenses increased to CNY 45,616,664.43, compared to CNY 34,777,434.06, marking a 31.2% rise[46]. - Management expenses rose to CNY 49,729,584.17 from CNY 33,467,005.09, an increase of 48.5%[46]. Government Grants and Approvals - The company received government grants totaling ¥1,369,527.13 during the reporting period[9]. - The company received approval for the drug "Azithromycin Injection" for domestic registration, enhancing its product portfolio[20]. - The company entered the national medical insurance directory with several products, expanding market access[21]. Other Financial Metrics - The weighted average return on net assets was 3.53%, down 48.00% compared to the previous year[8]. - The company reported no overdue commitments from controlling shareholders or related parties during the reporting period[24]. - There were no violations regarding external guarantees during the reporting period[26]. - The company did not experience any non-operating fund occupation by controlling shareholders or related parties[27].

Financial Performance - Total revenue for the first half of 2017 reached ¥130,085,466.97, representing a 26.14% increase compared to ¥103,124,707.55 in the same period last year[18]. - Net profit attributable to shareholders was ¥31,222,748.82, up 38.16% from ¥22,598,653.74 year-on-year[18]. - Net profit after deducting non-recurring gains and losses increased by 47.05%, totaling ¥30,079,651.27 compared to ¥20,455,240.28 in the previous year[18]. - Basic earnings per share rose to ¥0.29, a 16.00% increase from ¥0.25[18]. - The total profit for the period was CNY 34.45 million, an increase of 35.80% year-on-year[50]. - The net profit attributable to shareholders was CNY 31.22 million, up 38.16% from the previous year[50]. - The company achieved total operating revenue of 130.09 million, a year-on-year increase of 26.14%[35]. - The company reported a total operating cost of 30.12 million, which grew by 23.53% year-on-year, primarily due to increased sales costs of main products[35]. Cash Flow and Assets - Operating cash flow net amount surged by 240.88% to ¥26,286,676.12 from ¥7,711,368.54 in the same period last year[18]. - The company’s cash and cash equivalents at the end of the reporting period amounted to 308.28 million, an increase of 203.78% year-on-year, mainly due to funds raised from stock issuance[38]. - The company reported a net increase in cash and cash equivalents of ¥207,361,631.36, a drastic change from a decrease of ¥12,686,618.90 in the previous year, primarily due to fundraising activities[57]. - The total assets at the end of the reporting period were ¥755,008,427.32, reflecting a 71.70% increase from ¥439,721,630.51 at the end of the previous year[18]. - The company’s total current assets amounted to RMB 409,759,327.99, compared to RMB 174,592,853.03 at the beginning of the period, showing a growth of approximately 134.9%[145]. - Cash and cash equivalents rose to CNY 123,091,305.91, up 73.5% from CNY 70,919,222.37[149]. Investments and R&D - Research and development expenses increased by 58.60% to ¥18,114,106.06 from ¥11,421,018.45, reflecting a significant investment in innovation[56]. - The company is investing 200 million RMB in R&D for new drug development, focusing on innovative therapies[93]. - The company has approximately 70 ongoing research projects, primarily focused on cardiovascular, gastrointestinal, and non-steroidal anti-inflammatory diseases[41]. - The company raised CNY 314.35 million through its initial public offering, which will be used for the construction of a production line with an annual capacity of 1.5 billion dosage forms and a research and development center[50]. Market and Product Development - The company’s main product, Desloratadine, is included in the National Medical Insurance Directory, with 14 varieties classified as Class A and 13 as Class B[27]. - The company has entered the international research and sales of injection products, with several products having received approvals from the FDA and other international bodies[37]. - The company is actively involved in the development of controlled-release formulations and has a strong technical reserve in coating and solubilization technologies[27]. - The company has signed exclusive sales contracts with distributors in Europe and the United States, expanding its international market presence[42]. - Future guidance indicates an expected revenue growth of 18% for the second half of 2017, driven by new product launches[92]. Risks and Challenges - The company faces risks related to industry policies, price reductions in bidding, drug research and development, mergers and acquisitions, goodwill impairment, and new projects not meeting expectations[4]. - The company faces risks related to drug price declines due to the cancellation of government pricing for most drugs, which may lead to uncertainty in pricing and negatively impact profitability[82]. - There is a risk of losing bids or experiencing significant price drops in centralized procurement, which could affect local sales and revenue[83]. - Fluctuations in the supply and prices of key raw materials could impact the company's profitability, despite a competitive market for these materials[84]. Corporate Governance and Compliance - The company has established a comprehensive quality management system, ensuring that every production control point is verified by the quality assurance department[33]. - The financial report for the half-year period was not audited[100]. - The company has not faced any penalties or rectification issues during the reporting period[103]. - The company has made commitments to minimize related party transactions[99]. Shareholder Information - The total number of shareholders at the end of the reporting period was 13,051[127]. - The largest shareholder, Fan Minhua, holds 35.16% of the shares, totaling 42,932,000 shares[127]. - The company issued 30,529,405 shares at a price of CNY 11.49 per share, which began trading on March 28, 2017[126].

Financial Performance - Total revenue for Q1 2017 reached ¥48,232,478.57, representing a 34.04% increase compared to ¥35,984,807.33 in the same period last year[7] - Net profit attributable to shareholders was ¥10,354,472.51, up 25.43% from ¥8,255,216.66 year-on-year[7] - Net profit after deducting non-recurring gains and losses was ¥11,528,044.44, reflecting a 17.12% increase from ¥9,842,872.82 in the previous year[7] - The net cash flow from operating activities was ¥952,744.20, an increase of 25.65% compared to ¥758,248.05 in the same period last year[7] - Total operating revenue for the current period reached ¥48,232,478.57, up from ¥35,984,807.33 in the previous period, representing a growth of approximately 34%[42] - Operating profit for the current period was ¥11,528,044.44, compared to ¥9,842,872.82 in the previous period, indicating an increase of approximately 17%[43] - The total profit for the current period was ¥12,079,676.68, compared to ¥9,834,254.91 in the previous period, showing an increase of approximately 23%[43] - Basic and diluted earnings per share improved to ¥0.11 from ¥0.09, marking a growth of approximately 22%[44] Assets and Liabilities - Total assets at the end of the reporting period were ¥775,056,527.52, a significant increase of 76.26% from ¥439,721,630.51 at the end of the previous year[7] - Net assets attributable to shareholders reached ¥643,490,383.46, up 109.51% from ¥307,147,066.91 at the end of the previous year[7] - Current assets increased significantly to CNY 484.73 million from CNY 174.59 million, representing a growth of 177.5%[34] - Total liabilities decreased marginally to CNY 131.57 million from CNY 132.57 million, a reduction of 0.8%[36] - Owner's equity increased significantly to CNY 643.49 million from CNY 307.15 million, representing a growth of 109.5%[37] - Non-current assets totaled CNY 290.32 million, up from CNY 265.13 million, indicating a growth of 9.5%[35] Shareholder Information - The total number of common shareholders at the end of the reporting period was 55,153[17] - The top shareholder, Fan Minhua, holds 35.16% of the shares, amounting to 42,932,000 shares[17] Procurement and Sales - The total procurement amount from the top five suppliers was RMB 5,143,754.28, which is a 46.74% increase compared to the previous year[24] - The total sales amount from the top five customers was RMB 8,729,912.53, representing a significant increase of 275.45% year-on-year[25] - The proportion of total procurement from the top five suppliers was 52.31% during the reporting period[24] Cash Flow and Expenses - Cash inflow from operating activities totaled ¥67,106,025.94, significantly higher than ¥40,097,992.98 in the previous period, representing an increase of about 67%[50] - Sales expenses rose to ¥12,001,564.22 from ¥9,141,413.06, reflecting an increase of approximately 31%[43] - Management expenses increased to ¥13,049,268.65 from ¥7,106,617.47, indicating a rise of about 83%[43] - Tax expenses for the current period were ¥1,725,204.17, up from ¥1,579,038.25, which is an increase of about 9%[43] - The company paid 11,156,003.07 CNY in taxes during the period, compared to 7,722,534.21 CNY in the previous period, representing a 44% increase[53] - Cash outflow for employee payments was 4,346,567.65 CNY, up from 3,834,255.62 CNY, indicating a rise in labor costs[53] Risks and Compliance - The company faces risks related to drug price declines due to the removal of government pricing for most drugs, which may affect profitability[9] - The company is undertaking consistency evaluations for its products as mandated by the government, which could impact product registration and sales if not completed on time[12] - The company must adapt its marketing strategies to comply with the "two-invoice system" policy, which could affect drug sales and overall performance[14] Operational Status - The company has 27 products included in the National Medical Insurance Directory, with 14 in Category A and 13 in Category B[10] - The company has not experienced any significant changes in its core technology team or key technical personnel during the reporting period[23] - The company is actively implementing its annual business plan without any major adjustments[25] - There were no violations regarding external guarantees during the reporting period[28] - The company did not conduct an audit for the first quarter report[57]

Financial Performance - Total revenue for Q1 2017 reached ¥48,232,478.57, an increase of 34.04% compared to ¥35,984,807.33 in the same period last year[7] - Net profit attributable to shareholders was ¥10,354,472.51, up 25.43% from ¥8,255,216.66 year-on-year[7] - Net profit after deducting non-recurring gains and losses was ¥11,528,044.44, reflecting a 17.12% increase from ¥9,842,872.82 in the previous year[7] - The net cash flow from operating activities was ¥952,744.20, a rise of 25.65% compared to ¥758,248.05 in the same period last year[7] - Total operating revenue for the current period reached ¥48,232,478.57, up from ¥35,984,807.33 in the previous period, representing a growth of approximately 34.5%[41] - Net profit for the current period was ¥10,354,472.51, compared to ¥8,255,216.66 in the previous period, indicating an increase of approximately 25.5%[42] - The company reported a total profit of ¥12,079,676.68, up from ¥9,834,254.91, which is an increase of approximately 22.6%[42] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥775,056,527.52, representing a 76.26% increase from ¥439,721,630.51 at the end of the previous year[7] - Total current assets increased to CNY 484,732,513.10 from CNY 174,592,853.03, representing a growth of approximately 177.5%[33] - Total non-current assets rose to CNY 290,324,014.42 from CNY 265,128,777.48, an increase of approximately 9.5%[34] - Total liabilities decreased slightly to CNY 131,566,144.06 from CNY 132,574,563.60, a reduction of approximately 0.8%[35] - Shareholders' equity increased significantly to CNY 643,490,383.46 from CNY 307,147,066.91, representing a growth of about 109.5%[36] - The total liabilities and equity reached CNY 775,056,527.52, consistent with the total assets, indicating a balanced financial position[36] Shareholder Information - The total number of common shareholders at the end of the reporting period was 55,153[17] - The top shareholder, Fan Minhua, holds 35.16% of the shares, amounting to 42,932,000 shares[17] Sales and Procurement - The total procurement amount from the top five suppliers was CNY 5,143,754.28, an increase of 46.74% year-on-year[24] - The total sales amount from the top five customers was CNY 8,729,912.53, representing a significant increase of 275.45% compared to the previous year[25] - The proportion of sales from the top five customers accounted for 19.48% of total sales during the reporting period[25] Operational Challenges and Strategies - The company faces risks related to drug price declines due to the removal of government pricing for most drugs, which may affect profitability[9] - The company is undertaking consistency evaluations for its products as mandated by regulations, which could impact product registration and sales if not completed on time[12] - The company must adapt its marketing strategies to comply with the "two-invoice system" policy to mitigate potential negative impacts on drug sales[14] - The company is focusing on expanding its market presence and enhancing product development strategies to drive future growth[42] Cash Flow and Expenses - Cash flow from operating activities totaled ¥67,106,025.94, significantly higher than ¥40,097,992.98 in the previous period[49] - Total cash outflow from operating activities amounted to 66,153,281.74 CNY, compared to 39,339,744.93 CNY in the previous period, reflecting a significant increase in operational expenses[50] - The net cash flow from investing activities was -27,663,438.03 CNY, showing a decrease from -34,001,198.32 CNY, indicating reduced investment outflows[51] - Cash inflow from financing activities reached 326,782,863.45 CNY, a substantial increase compared to the previous period where there was no recorded inflow[51] - The net cash flow from financing activities was 326,234,924.44 CNY, a significant recovery from -14,354,134.58 CNY in the previous period, highlighting improved financing conditions[51] - The total cash and cash equivalents at the end of the period were 400,537,974.51 CNY, a notable increase from 48,778,057.23 CNY in the previous period[51] - The company reported a cash flow deficit from operating activities of -19,708,795.94 CNY, an improvement from -26,521,487.22 CNY in the previous period[52] - Cash outflow for purchasing goods and services was 26,562,860.08 CNY, down from 40,985,405.40 CNY, indicating cost control measures[52] - The cash inflow from operating activities totaled 30,102,193.52 CNY, a decrease from 31,665,396.22 CNY, suggesting a slight decline in revenue generation[52]